Prevention of TGFβ Induction Attenuates AngII-stimulated Vascular Biglycan and Atherosclerosis in Ldlr-/- Mice

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2013 Jun 11

PMID 23749984

Citations 11

Authors

Tao Tang

Patricia G Wilson

Joel C Thompson

Christina Nelson

Meghan H Yoder

Lisa R Tannock

Affiliations

Soon will be listed here.

Abstract

Angiotensin II (angII) accelerates atherosclerosis, but the mechanisms are not fully understood. The aim of this study was to determine whether TGFβ is required for angII-induced atherosclerosis. Ldlr-null mice fed a normal chow diet were infused with angII or saline for 28 days. A single injection of TGFβ neutralizing antibody 1D11 (2 mg/kg) prevented angII-induction of TGFβ1 levels, and strikingly attenuated angII-induced accumulation of aortic biglycan content. To study atherosclerosis, mice were infused with angII or saline for 4 weeks, and then fed Western diet for a further 6 weeks. 1D11 had no effect on systolic blood pressure or plasma cholesterol; however, angII-infused mice that received 1D11 had reduced atherosclerotic lesion area by 30% (P < 0.05). Immunohistochemical analyses demonstrated that angII induced both lipid retention and accumulation of biglycan and perlecan which colocalized with apoB. 1D11 strikingly reduced the effect of angII on biglycan but not perlecan. 1D11 decreased total collagen content (P < 0.05) in the lesion area without changing plaque inflammation markers (CD68 and CD45). Thus, this study demonstrates that neutralization of TGFβ attenuated angII stimulation of biglycan accumulation and atherogenesis in mice, suggesting that TGFβ-mediated biglycan induction is one of the mechanisms underlying angII-promoted atherosclerosis.

Citing Articles

Stable CAD patients show higher levels of platelet-borne TGF-β1 associated with a superior pro-inflammatory state than the pro-aggregatory status; Evidence highlighting the importance of platelet-derived TGF-β1 in atherosclerosis.

Ahmadi J, Hosseini E, Kargar F, Ghasemzadeh M J Thromb Thrombolysis. 2022; 55(1):102-115.

PMID: 36352058 DOI: 10.1007/s11239-022-02729-y.

Angiotensin II, Hypercholesterolemia, and Vascular Smooth Muscle Cells: A Perfect Trio for Vascular Pathology.

St Paul A, Corbett C, Okune R, Autieri M Int J Mol Sci. 2020; 21(12).

PMID: 32630530 PMC: 7350267. DOI: 10.3390/ijms21124525.

TGFβ, smooth muscle cells and coronary artery disease: a review.

Low E, Baker A, Bradshaw A Cell Signal. 2018; 53:90-101.

PMID: 30227237 PMC: 6293316. DOI: 10.1016/j.cellsig.2018.09.004.

A role for proteoglycans in vascular disease.

Wight T Matrix Biol. 2018; 71-72:396-420.

PMID: 29499356 PMC: 6110991. DOI: 10.1016/j.matbio.2018.02.019.

Elevated circulating TGF-β is not the cause of increased atherosclerosis development in biglycan deficient mice.

Thompson J, Wilson P, Wyllie A, Wyllie A, Tannock L Atherosclerosis. 2017; 268:68-75.

PMID: 29182988 PMC: 5750111. DOI: 10.1016/j.atherosclerosis.2017.11.005.

References

Figueroa J, Vijayagopal P . Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis. 2002; 162(2):261-8. DOI: 10.1016/s0021-9150(01)00714-6. View

Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky V . Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol. 2002; 22(6):975-82. DOI: 10.1161/01.atv.0000019729.39500.2f. View

Hollmann J, Schmidt A, von Bassewitz D, Buddecke E . Relationship of sulfated glycosaminoglycans and cholesterol content in normal and arteriosclerotic human aorta. Arteriosclerosis. 1989; 9(2):154-8. DOI: 10.1161/01.atv.9.2.154. View

Grainger D, Kemp P, Metcalfe J, Liu A, Lawn R, Williams N . The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1995; 1(1):74-9. DOI: 10.1038/nm0195-74. View

Grainger D . TGF-beta and atherosclerosis in man. Cardiovasc Res. 2007; 74(2):213-22. DOI: 10.1016/j.cardiores.2007.02.022. View

Daugherty A, Lu H, Rateri D, Cassis L . Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases. Future Lipidol. 2009; 3(6):625-636. PMC: 2636897. DOI: 10.2217/17460875.3.6.625. View

Kunjathoor V, Chiu D, OBrien K, LeBoeuf R . Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2002; 22(3):462-8. DOI: 10.1161/hq0302.105378. View

Dreher K, Asundi V, Matzura D, Cowan K . Vascular smooth muscle biglycan represents a highly conserved proteoglycan within the arterial wall. Eur J Cell Biol. 1990; 53(2):296-304. View

Huang F, Thompson J, Wilson P, Aung H, Rutledge J, Tannock L . Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res. 2007; 49(3):521-30. DOI: 10.1194/jlr.M700329-JLR200. View

10.

Nabel E, Shum L, Pompili V, Yang Z, San H, Shu H . Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993; 90(22):10759-63. PMC: 47857. DOI: 10.1073/pnas.90.22.10759. View

11.

Frutkin A, Otsuka G, Stempien-Otero A, Sesti C, Du L, Jaffe M . TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2009; 29(9):1251-7. PMC: 2740721. DOI: 10.1161/ATVBAHA.109.186593. View

12.

Li D, Liu Y, Chen J, Velchala N, Amani F, Nemarkommula A . Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice. Biochem Biophys Res Commun. 2006; 344(3):701-7. DOI: 10.1016/j.bbrc.2006.04.010. View

13.

Krauss R, La Belle M, Blanche P, Barrett P, Wight T, Chait A . ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res. 2002; 43(11):1969-77. DOI: 10.1194/jlr.m200322-jlr200. View

14.

Tannock L, King V . Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord. 2008; 9(4):289-300. DOI: 10.1007/s11154-008-9078-0. View

15.

Kagami S, Border W, Miller D, Noble N . Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994; 93(6):2431-7. PMC: 294451. DOI: 10.1172/JCI117251. View

16.

Tiede K, Stoter K, Petrik C, Chen W, Ungefroren H, Kruse M . Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro. Cardiovasc Res. 2003; 60(3):538-46. DOI: 10.1016/j.cardiores.2003.08.009. View

17.

Nagy N, Melchior-Becker A, Fischer J . Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis. Basic Res Cardiol. 2009; 105(1):29-38. DOI: 10.1007/s00395-009-0051-1. View

18.

Buday A, orsy P, Godo M, Mozes M, Kokeny G, Lacza Z . Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoE(-/-) mice. Am J Physiol Heart Circ Physiol. 2010; 299(2):H386-95. PMC: 5504387. DOI: 10.1152/ajpheart.01042.2009. View

19.

Schonherr E, Jarvelainen H, Kinsella M, Sandell L, Wight T . Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb. 1993; 13(7):1026-36. DOI: 10.1161/01.atv.13.7.1026. View

20.

Grainger D, Mosedale D, Metcalfe J, Bottinger E . Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci. 2000; 113 ( Pt 13):2355-61. DOI: 10.1242/jcs.113.13.2355. View